The CTLs lysed MCF-7 breast cancer cells (MUC1+, HLA-A*0201), produced IFNγ, and showed cross-reactivity with the native P1:STAPPVHNV peptide, suggesting these analog peptides may offer substantial improvements in the design of epitope-based vaccines. Here, MUC1 is linked to breast cancer.